[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 5 of about 5
1. Kolomecki K, Stepien H, Bartos M, Kuzdak K: Usefulness of VEGF, MMP-2, MMP-3 and TIMP-2 serum level evaluation in patients with adrenal tumours. Endocr Regul; 2001 Mar;35(1):9-16
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To estimate serum levels of vascular endothelial growth factor (VEGF), metalloproteases MMP-2 (gelatinase A), MMP-3 (stromyelisine 1) and metalloprotease tissue inhibitors (TIMP-2) in patients with various benign and malignant adrenal tumours before and after surgery, as well as to evaluate if there is a correlation between serum levels of these agents and tumour types.
  • METHODS: Serum levels of VEGF, MMP-2, -3 and TIMP-2 were estimated in 43 patients with adrenal tumour at the admission and, in case of surgery, again one month after surgery.
  • The patients were divided into 6 groups according to the type of the tumour (I - patients with adrenal cortex carcinoma, II - with benign hormonally active adrenocortical adenomas, III - with benign, hormonally inactive adenocortical adenomas (incidentaloma), IV - with benign, hormonally active phaeochromocytomas, V - with hormonally quiescent phaeochromocytomas, VI - hormonally inactive adrenal tumours of extraglandular origin.
  • RESULTS: There was no correlation between MMP-2 serum levels and tumour types and no significant difference between MMP-2 level before and after surgery.
  • Significant increase of serum MMP-3 level was found in patients with cortex cancer and hormonally active benign adrenocortical tumours.
  • The MMP-3 mean serum level was also significantly higher in patients with malignant incidentalomas than in those with benign ones.
  • In all groups of patients with adrenal tumours the means serum VEGF level was significantly higher than in control patients, and it was also significantly higher in patients with malignant incidantalomas than in those with benign ones.
  • CONCLUSIONS: Since MMP-3 and VEGF serum levels were found significantly higher in patients with malignant adrenal incidentalomas than in those with benign ones, they might be applied as markers of malignancy of incidentalomas.
  • VEGF and MMP-3 levels decreased after tumour resection in all patients with malignant tumors and increased significantly in patients with recurrence.
  • [MeSH-major] Adrenal Gland Neoplasms / blood. Endothelial Growth Factors / blood. Lymphokines / blood. Matrix Metalloproteinase 2 / blood. Matrix Metalloproteinase 3 / blood. Tissue Inhibitor of Metalloproteinase-2 / blood
  • [MeSH-minor] Adenoma / blood. Adenoma / surgery. Adrenal Cortex Neoplasms / blood. Adrenal Cortex Neoplasms / surgery. Adrenalectomy. Adult. Aged. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Pheochromocytoma / blood. Pheochromocytoma / surgery. Vascular Endothelial Growth Factor A. Vascular Endothelial Growth Factors

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11308991.001).
  • [ISSN] 1210-0668
  • [Journal-full-title] Endocrine regulations
  • [ISO-abbreviation] Endocr Regul
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Slovakia
  • [Chemical-registry-number] 0 / Endothelial Growth Factors; 0 / Lymphokines; 0 / Vascular Endothelial Growth Factor A; 0 / Vascular Endothelial Growth Factors; 127497-59-0 / Tissue Inhibitor of Metalloproteinase-2; EC 3.4.24.17 / Matrix Metalloproteinase 3; EC 3.4.24.24 / Matrix Metalloproteinase 2
  •  go-up   go-down


2. Timmers HJ, Brouwers FM, Hermus AR, Sweep FC, Verhofstad AA, Verbeek AL, Pacak K, Lenders JW: Metastases but not cardiovascular mortality reduces life expectancy following surgical resection of apparently benign pheochromocytoma. Endocr Relat Cancer; 2008 Dec;15(4):1127-33
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastases but not cardiovascular mortality reduces life expectancy following surgical resection of apparently benign pheochromocytoma.
  • The treatment of choice for non-metastatic pheochromocytoma is surgical resection.
  • Its goals are to abolish catecholamine hypersecretion, normalize blood pressure, and prevent further tumor growth or progression to metastatic disease.
  • We here report a retrospective study on the long-term outcome after surgery for apparently benign pheochromocytoma at the Radboud University Nijmegen Medical Centre.
  • Survival was compared with survival of a matched reference population.
  • Two patients experienced a benign recurrence. Mean+/-s.d. follow-up was 10.2+/-7.5 (median 9, range 1-38) years.
  • In conclusion, compared with the general population patients have a reduced life expectancy following pheochromocytoma surgery, due to their risk of developing metastatic disease.
  • Only one-third becomes normotensive without antihypertensive medication.
  • [MeSH-major] Adrenal Gland Neoplasms / pathology. Adrenal Gland Neoplasms / surgery. Cardiovascular Diseases / mortality. Life Expectancy. Pheochromocytoma / secondary. Pheochromocytoma / surgery
  • [MeSH-minor] Adult. Aged. Blood Pressure. Catecholamines / blood. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / mortality. Neoplasm Recurrence, Local / surgery. Prognosis. Retrospective Studies. Survival Rate. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Pheochromocytoma.
  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • MedlinePlus Health Information. consumer health - Pheochromocytoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18824558.001).
  • [ISSN] 1351-0088
  • [Journal-full-title] Endocrine-related cancer
  • [ISO-abbreviation] Endocr. Relat. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Catecholamines
  •  go-up   go-down


3. Sorianello E, Schillaci R, Chamson-Reig A, Lux-Lantos V, Libertun C: Actions of immunosuppressor drugs on the development of an experimental ovarian tumor. Exp Biol Med (Maywood); 2002 Sep;227(8):658-64
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Actions of immunosuppressor drugs on the development of an experimental ovarian tumor.
  • Immunosuppression has been related to the incidence of tumor apparition, including endocrine tumors.
  • The intrasplenic ovarian tumor (luteoma) is a typical benign endocrine tumor that develops under high gonadotropin stimulation and, from the immunological perspective, is located in a critical organ involved in immune response.
  • To establish if immunosuppression could alter the development of this experimental tumor, the effects of cyclosporin A (CsA) and dexamethasone (Dex) were evaluated.
  • After surgery, tumor-bearing and sham animals were kept without treatment for 4 weeks; thereafter, they were distributed into CsA (25 mg/kg), Dex (0.1 mg/kg), or vehicle (75:25 castor oil:ethanol) groups and were injected on alternate days for 50 days.
  • Animals were sacrificed after a jugular vein blood sample was obtained.
  • CsA induced a significant decrease in survival rates both in tumor-bearing and sham animals (P < 0.01).
  • Dex significantly impaired weight increase in both groups of animals.
  • CsA induced a significant weight loss in sham animals, not observed in tumor-bearing animals.
  • Dex induced thymus weight loss in both groups, whereas CsA induced thymus weight loss only in sham animals.
  • CsA induced an increase in monocyte number only in sham animals.
  • Neither Dex nor CsA induced any significant variations in tumor volume, nor did they alter tumor histology.
  • We conclude that, though immunological parameters were altered by the treatments, immunosuppressor drugs did not condition tumor development.
  • [MeSH-major] Cyclosporine / pharmacology. Dexamethasone / pharmacology. Immunosuppressive Agents / pharmacology. Luteoma / pathology. Ovarian Neoplasms / pathology. Spleen / pathology
  • [MeSH-minor] Animals. Body Weight / drug effects. Estradiol / blood. Female. Follicle Stimulating Hormone / blood. Immunocompromised Host. Luteinizing Hormone / blood. Neoplasm Transplantation. Organ Size / drug effects. Ovariectomy. Ovary / transplantation. Prolactin / blood. Rats. Rats, Sprague-Dawley. Thymus Gland / pathology. Transplantation, Heterotopic

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. ESTRADIOL .
  • Hazardous Substances Data Bank. CYCLOSPORIN A .
  • Hazardous Substances Data Bank. MENOTROPINS .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12192110.001).
  • [ISSN] 1535-3702
  • [Journal-full-title] Experimental biology and medicine (Maywood, N.J.)
  • [ISO-abbreviation] Exp. Biol. Med. (Maywood)
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunosuppressive Agents; 4TI98Z838E / Estradiol; 7S5I7G3JQL / Dexamethasone; 83HN0GTJ6D / Cyclosporine; 9002-62-4 / Prolactin; 9002-67-9 / Luteinizing Hormone; 9002-68-0 / Follicle Stimulating Hormone
  •  go-up   go-down


Advertisement
4. Camera A, Magri F, Fonte R, Villani L, Della Porta MG, Fregoni V, Manna LL, Chiovato L: Burkitt-like lymphoma infiltrating a hyperfunctioning thyroid adenoma and presenting as a hot nodule. Thyroid; 2010 Sep;20(9):1033-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Most solitary hyperfunctiong regions on thyroid scan consist of benign tissue.
  • SUMMARY: A 56-year-old man was referred to our Endocrine Unit in May 2009 due to the incidental discovery of a large left thyroid lobe nodule by a computed tomography study.
  • This had been performed to search for a primitive tumor in a patient with bone metastasis.
  • Histological analysis of the surgical specimen led to a diagnosis of Burkitt-like large B-cell lymphoma harbored within a thyroid adenoma.
  • After further staging, the final diagnosis was stage IV E Burkitt-like lymphoma with the involvement of the bone and the thyroid.
  • CONCLUSIONS: Involvement of the thyroid gland by Burkitt-like lymphoma is extremely rare as is close localization of malignancy and a hyperfunctioning thyroid nodule.
  • As highlighted by the present report, performing fine-needle aspiration cytology should be always considered in the clinical context of a metastatic disease of unknown origin or when there are ultrasonography signs suggesting malignancy, even when the nodule is hyperfunctioning.
  • [MeSH-major] Adenoma / diagnosis. Burkitt Lymphoma / diagnosis. Thyroid Neoplasms / diagnosis. Thyroid Nodule / diagnosis
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biopsy, Fine-Needle. Bone Neoplasms / secondary. Cyclophosphamide / therapeutic use. Dexamethasone / therapeutic use. Doxorubicin / therapeutic use. Humans. Hyperthyroidism / drug therapy. Hyperthyroidism / surgery. Male. Methimazole / therapeutic use. Middle Aged. Neoplasm Staging. Technetium. Vincristine / therapeutic use

  • Genetic Alliance. consumer health - Thyroid Lymphoma.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. METHIMAZOLE .
  • Hazardous Substances Data Bank. TECHNETIUM, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20825299.001).
  • [ISSN] 1557-9077
  • [Journal-full-title] Thyroid : official journal of the American Thyroid Association
  • [ISO-abbreviation] Thyroid
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 554Z48XN5E / Methimazole; 5J49Q6B70F / Vincristine; 7440-26-8 / Technetium; 7S5I7G3JQL / Dexamethasone; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide
  •  go-up   go-down


5. Fraker DL: Update on the management of parathyroid tumors. Curr Opin Oncol; 2000 Jan;12(1):41-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Parathyroid tumors are virtually always benign with an estimated incidence of parathyroid carcinoma causing hyperparathyroidism in only .017% of cases.
  • Virtually all parathyroid neoplasms, including the rare parathyroid carcinoma, are functional and discussion of the management of parathyroid tumors is tantamount to the discussion of primary hyperparathyroidism.
  • The biochemical diagnostic criteria with rare exception is definitive, and the key issue with this functional benign endocrine neoplasm is when to recommend operation and how to ensure optimal results in this curable disease.
  • The sestamibi nuclear medicine scan has become the best tool available for imaging of abnormal parathyroid glands.
  • For multi-gland parathyroid disease or hyperplasia, the sensitivity of this test is decreased.
  • For the rare patients with parathyroid carcinoma, aggressive surgical resection with en bloc removal of any adjacent invading structures is the best chance for cure leading to 10-year survival rates of 49%.
  • [MeSH-major] Parathyroid Neoplasms
  • [MeSH-minor] Adult. Age Factors. Diagnosis, Differential. Humans. Hyperparathyroidism. Kidney Calculi / etiology. Middle Aged. Osteoporosis / etiology. Pain / etiology. Parathyroidectomy. Prognosis

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10687728.001).
  • [ISSN] 1040-8746
  • [Journal-full-title] Current opinion in oncology
  • [ISO-abbreviation] Curr Opin Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] UNITED STATES
  • [Number-of-references] 28
  •  go-up   go-down






Advertisement